Slides
Page 1
Solving problems for healthcare H1 26 Preliminary Results Presentation
Page 2
Important Notice This presentation has been prepared solely in connection with the financial results of Uniphar plc (the "Company") for the period ended 30 June 2026 and should be read in conjunction with the announcement of the interim results of the Company for the period ended 30 June 2026, released 08 September 2026 (the “2026 Interim Results Announcement”). For the purposes of this notice, the presentation that follows shall mean and include the slides that follow, the oral presentation of the slides by the Company, the question-and-answer session that follows that oral presentation, hard and electronic copies of this document and any materials distributed at, or in connection with, that presentation. This presentation is not intended to and does not constitute or form part of any offer, or invitation, or solicitation of any offer to issue, underwrite, subscribe for, or otherwise acquire or dispose of any shares or other securities of the Company in any jurisdiction or an inducement to enter into investment activity. No part of this presentation, nor the fact of its distribution, should form the basis of, or be relied on in connection with, any contract or commitment or investment decision whatsoever. No representation or warranty, express or implied, is given by or on behalf of the Company, its group companies, or any of their respective shareholders, directors, officers, employees, advisers, agents or any other persons as to the accuracy, completeness, fairness or sufficiency of the information, projections, forecasts or opinions contained in this presentation. Save in the case of fraud, no liability is accepted for any errors, omissions or inaccuracies in any of the information or opinions in this presentation and neither the Company and its group companies nor any of their respective employees, officers, directors, advisers, representatives, agents or affiliates, shall have any liability whatsoever (in negligence or otherwise, whether direct or indirect, in contract, tort or otherwise) for any loss howsoever arising from any use of this presentation or its contents or otherwise arising in connection with this presentation. Certain information contained in this presentation has been obtained from published and non-published sources prepared by other parties, which in certain cases have not been updated to the date hereof. While such information is believed to be reliable for the purpose used in this presentation, the Company does not assume any responsibility for the accuracy or completeness of such information and which has not been independently verified by the Company. Except where otherwise indicated herein, the information provided in this presentation is based on matters as they exist as of the date of preparation and not as of any future date, and will not be updated or otherwise revised to reflect information that subsequently becomes available, or circumstances existing or changes occurring after the date hereof. This presentation contains certain projections and other forward-looking statements with respect to the financial condition, results of operations, businesses and prospects of the Company and its group companies. These statements are based on current expectations and involve risk and uncertainty because they relate to events and depend upon circumstances that may or may not occur in the future. There are a number of factors which could cause actual results or developments to differ materially from those expressed or implied by these projections and forward-looking statements. Any of the assumptions underlying these projections and forward-looking statements could prove inaccurate or incorrect and therefore any results contemplated in the projections and forward- looking statements may not actually be achieved. Recipients are cautioned not to place undue reliance on any projections and forward-looking statements contained herein. Except as required by law or by any appropriate regulatory authority, the Company and its group companies undertake no obligation to update or revise (publicly or otherwise) any projection or forward-looking statement, whether as a result of new information, future events or other circumstances. Your attention is drawn to the ‘Principal Risks and Uncertainties’ set out in the Company’s 2025 Annual Report. The risks described, however, are not exhaustive and there may be other risks which may have an adverse effect on the business, financial condition, results or future prospects of the Company. The H1 2026 financial information set out in this document is unaudited. For further information see www.uniphar.com 2
Page 3
Agenda 3 01 02 03 Overview & Highlights Divisional Review Investment Update 04 05 Financial Review Capital Allocation & Investment Case Ger Rabbette Chief Executive Officer Tim Dolphin Chief Financial Officer Brian O'Shaughnessy Chief Commercial Officer Dermot Ryan Chief Operating Officer 06 Q&A Call Participants
Page 4
Overview & Highlights 4
Page 5
A diversified international healthcare services provider €1.6bn 160+ 4 200 Uniphar at a glance 5 Supporting 200 multinational pharmaceutical and medtech manufacturers across three divisions Active in Europe, North America, APAC and MENA Delivering to 160+ countries In H1 26, the Group generated revenue of €1.6bn, gross profit of €236.5m and EBITDA of €61.1m €200m EBITDA target by 2028 At least 80% of growth to be organic
Page 6
Product approval Pricing and payment Access key opinion leaders Finding patients Educating key stakeholders Patient access to products Getting product to patients Healthcare manufacturers Medtech 7 of the top 10 are Uniphar clients Large pharma All of the top 10 are Uniphar clients Biotech We are the leading global player in Cell and Gene access Healthcare stakeholders Patients Doctors / consultants Hospital / retail pharmacies Regulatory agencies Government & other payors Solving problems for healthcare 6
Page 7
H1’25 H1’26 Financial Highlights 7 Strong progress during the period Organic gross profit growth of 6.9% ROCE of 14.7% within our 12-15% target2 Leverage of 2.4x EPS growth of 11.2% FCF conversion of -77%1 1. Free cashflow is defined as EBITDA, less investment in working capital, less maintenance capital expenditure, less principal and interest payments on leases, less foreign exchange translation adjustment divided by EBITDA 2. See slide 36 EBITDA growth of 6.2%, to accelerate H2 Organic gross profit growth across all divisions 6.9% organic growth SC&R Medtech Pharma M&A €6m €5m €4m €2m €220m €236m FX (€1m)
Page 8
10.1 24.8 2019 2025 EPS1 (cent) Our strong track record since IPO 8 180.6 457.7 2019 2025 Gross Profit (€m) Margins (%) 10.8 14.9 2019 2025 3.5 4.3 2019 2025 Gross margin EBITDA margin 58.6 130.9 2019 2025 EBITDA (€m) 1. Adjusted EPS has been calculated based on 2025 weighted average shares in issue
Page 9
Sustainability Highlights 9 Sustainability is at the core of what we do and is deeply embedded in our business strategy Environment • Climate Change • Resource Use & Circular Economy Governance • Business Conduct • Compliance with UK code Social • Our People • Workers in our Supply Chain • Our Patients Uniphar ranks 8th out of 621 healthcare companies globally ‘Committed’ ecovadis ratingCDP ‘B’ Rating
Page 10
Divisional Review 10
Page 11
3 divisions serving our healthcare customers 11 Ireland Mass market Infrastructure play Global Speciality High growth Europe Speciality High growth 44% % of Group gross profit % of Group gross profit 29% % of Group gross profit 27%
Page 12
Structural Drivers 12 Biotech Account for 85% of global development pipeline and 60% of all drugs launched in US. Very limited infrastructure ex US Supply chain complexity Consolidation of generic manufacturing and greater product complexity (biologics/ cold chain) driving shortages Large pharma Increasingly focused on larger markets only Patient/HCP awareness Greater patient and HCP awareness of new medicines available outside their own market
Page 13
How Uniphar Pharma wins 13 Global platform Leveraging global capabilities and a common platform to deliver high value solutions to manufacturers and hospitals We accelerate patient access to medicines by facilitating global availability through licenced and unlicenced channels Huge global market opportunity Global Speciality High growth Global sourcing capability Common Uniphar infrastructure Global hospital channel Services for Pharma/Biotech Customers Services for Hospitals Solving any product access issues across unlicenced medicines, shortages and alternative products Support for speciality medicines from pre-reimbursement access through to peak sales % of Group gross profit 29%
Page 14
14 • Solid organic gross profit growth. New business momentum supports an acceleration in H2 26 • Leading platform meeting high demand for shortages, unlicenced medicines and clinical trial supplies • Accelerate patient access and time to achieving peak sales for innovative therapies • Continued investment in Global ex-US launch capability offering comprehensive end-to-end services Providing access to unlicensed and specialty medicines globally Revenue and Gross Profit Gross Profit Split EBITDA Gross Profit Growth Revenue €370m Gross profit €69m Reported 7.0% Organic 7.0% Ireland 25% Rest of World 40% EU 35% EBITDA €14.0m EBITDA margin 3.8% Growth drivers during H1 2026
Page 15
Structural Drivers 15 Large and fragmented European market The total European Medtech distribution market is worth over €60bn and is growing 3-4% p.a. Larger distribution platforms are expected to grow faster through market share gains and acquisitions Smaller players lack infrastructure There are a growing number of small, innovative manufacturers who lack infrastructure in Europe Shift from direct to indirect/hybrid Large manufacturers are moving from direct to indirect or hybrid models Portfolio change Manufacturers are increasingly divesting non- core portfolios to acquirers who may lack distribution infrastructure
Page 16
How Uniphar Medtech wins 16 European platform Full service medical device commercialisation model Expanding into new regions, specialties and services Multi-decade relationships with leading manufacturers Focus on consultant-led decision making High margin, high growth, long-term relationships Europe Speciality High growth Leading medtech manufacturers High value specialisms; Orthopedics Connected Care Interventional Diagnostic Imaging Surgical Ophthalmology Hospital consultants Global manufacturer relationships Uniphar healthcare professionals European hospital channel % of Group gross profit 27%
Page 17
17 • Very strong organic growth, with a healthy pipeline supporting continued momentum • Growth in all specialities • Travelled with existing suppliers into new regions • Live with new suppliers in all regions Sales, marketing and distribution solutions for manufacturers Growth drivers during H1 2026 Revenue and Gross Profit Gross Profit Split EBITDA Gross Profit Growth Revenue €152m Gross profit €63m Reported 9.0% Organic 9.0% Recurring Products and Service 87% Capital Equipment 13% EBITDA €24.1m EBITDA margin 15.9%
Page 18
How Uniphar SC+R wins 18 Ireland only platform Leading player in the Irish pharmaceutical market Vertically integrated across wholesale and retail channel Strong moat, high barriers to entry, highly cash generative Moving up the value chain into own brand consumer, partnerships, in-licencing and broader service offerings Ireland Mass market Infrastructure play Wholesale market leadership Buying groups Franchise groups Direct pharmacy ownership Consumer brands Rx in-licensing Retail market leadership Network of 512 pharmacies1 Global manufacturer relationships Uniphar Wholesale infrastructure Irish pharmacy channel 44% % of Group gross profit 1. 512 pharmacies includes owned, franchised and symbol group members
Page 19
19 • We continue to win market share in a growing Irish wholesale market • Strong wholesale growth across all categories • Retail seeing good growth in Rx and services, with a softening in front-of-shop • Symbol group expanded by 30 stores to 512 Leader in the Irish pharmaceutical market. Supported by a network of 512 pharmacies1 Revenue and Gross Profit Gross Profit Split EBITDA Gross Profit Growth Revenue €1,069m Gross profit €105m 1. 512 pharmacies includes owned, franchised and symbol group members Reported 7.3% Organic 5.6% Supply Chain 46% Retail 54% EBITDA €22.9m EBITDA Margin 2.1% Growth drivers during H1 2026 • New distribution centre go-live now February 2027
Page 20
Investment Update 20
Page 21
Infrastructure for €200m EBITDA and beyond 21 Dublin, Ireland Lelystad, The Netherlands North Carolina, US Midlands, UK US expansion: • Modern 65K square feet facility • 3,000 ambient storage locations • 300 cold chain pallet positions • Operational 2024 UK expansion: • BREEAM Excellent standard distribution centre • 110K square feet • 10,000 ambient storage locations • 800 cold chain pallet positions • Operational 2026 European expansion: • BREEAM Excellent standard distribution centre • 85K square feet • 10,000 ambient storage locations • 500 cold chain pallet positions • Operational 2025 Ireland expansion: • LEED Gold standard distribution centre • 330k square feet • 440,000 ambient storage locations • 1,200 cold chain pallet positions • Operational 2027
Page 22
Flagship Irish Distribution Facility 22 Return 12%-15% ROCE within 5 yrs, growing thereafter Drivers Aging population market growth at ≈2% annually Doubled our market share in 10 years to 50%+ Transform customer experience Distribution Capabilities Reduces direct pick costs by 50% & deliver better efficiency Pharmacy Enables Pharmacy of the Future with enhanced service offerings Capacity Futureproof capacity by >2x Market Share Growth Transforms the customer experience and will help drive further market share growth
Page 23
Irish Distribution Facility Update 23 June - Nov 26 Load testing completes & cut over activity begins Feb 27 Go Live commences Feb – Aug 27 Dual Running period • Go live in February 2027 • Phased roll-out during H1 2027 • Extended timeline allows for additional end- to-end testing and minimises execution risk during peak operational period in Q4 • Incremental capital expenditure of approximately €20m
Page 24
Financial Review 24
Page 25
Financial Highlights 25 % Growth (€m) H1’26 H1’25 Reported Constant currency1 Organic2 Revenue 1,591.8 1,485.5 7.2% 7.4% Gross profit 236.5 219.7 7.7% 8.2% 6.9% Gross profit margin 14.9% 14.8% EBITDA 61.1 57.5 6.2% 6.5% Adjusted EPS (Reported)3 10.9 9.8 11.2% Net bank debt/EBITDA 2.4x 1.9x 1. Constant currency growth is calculated by applying the prior period’s actual exchange rate to the current period’s result 2. Organic growth calculated as the growth from restated prior period earnings to current period earnings as a % of the restated prior period value. The restatement to the prior year value is to include the corresponding prior period performance of acquisitions and exclude the prior period performance of disposals 3. Adjusted EPS calculated based on weighted average shares in issue in H1 2026 period of 259.6m (H1 2025: 264.1m). Performed within guided ROCE 14.7% Double-digit adjusted EPS growth 11.2% Organic gross profit growth across all three divisions 6.9%
Page 26
Divisional Performance 26 Diversified healthcare services business focused on higher margin opportunities Gross profit EBITDA €’m Growth % Organic Growth % Margin €’m Growth % Margin 68.5 7.0% 7.0% 18.5% 14.0 3.9% 3.8% 62.7 9.0% 9.0% 41.2% 24.1 11.5% 15.9% 105.3 7.3% 5.6% 9.8% 22.9 2.4% 2.1% Total 236.5 7.7% 6.9% 14.9% 61.1 6.2% 3.8% Divisional Composition 44% 27% 29% H1’26 €236.5m GP 37% 40% 23% H1’26 €61.1m EBITDA
Page 27
Net Bank Debt1 Analysis 1. Net bank debt represents the net total of current and non-current borrowings, cash and cash equivalents. 2. Other of c.€11.6m includes exceptional costs of €5.1m, dividends of €3.4m, acquisition related costs of €2.9m & FX movements on cash €0.8m; offset by proceeds from sale of assets €0.3m & FX movements on cash €0.2m. YE 2025 EBITDA Net Working Capital Capex Strategic Capex H1 2026Tax €275.7m Net bank debt at 30 Jun 2026 (€47.0m) Free cashflow (FCF %: (77.1%)) 27 Lease Payments Finance Costs Other2 171.1 (61.1) 86.5 9.1 27.5 9.1 9.3 12.5 11.6 275.7 €36.6m Capital Expenditure
Page 28
FCF Conversion 60-70% conversion at €200m 2028 Target 28 Free cash flow Free Cashflow (FCF) €’m H1’26 H1’25 EBITDA 61.1 57.5 Net Working Capital (86.5) (17.1) Capital expenditure (9.1) (8.5) Lease payments (12.5) (11.7) FCF (47.0) 20.3 FCF Conversion (77.1%) 35.3% 1. Free cashflow is defined as EBITDA, less investment in working capital, less maintenance capital expenditure, less principal and interest payments on operating leases, less foreign exchange translation adjustment divided by EBITDA We target FCF1 conversion of 60-70% at €200m EBITDA Reported free cashflow during the period was (77.1%), reflecting the unwind of prior year working capital timing benefits
Page 29
Capital Allocation & Investment Case 29
Page 30
Creating shareholder value 30 Discipline and balanced investment approach Net Bank Debt • Not to exceed 2.5x in the medium-term • Balance sheet provides significant flexibility for the Group to execute on its strategy and meet its strategic goals Growth Through M&A • Fundamental component of compounding growth strategy • Active pipeline of acquisition opportunities • Subject to Group’s strict ROCE hurdle rate of 12% - 15% within three years Organic Investment • Continue to invest in infrastructure, digital platforms, strategic capex and talent to drive organic growth in line with new medium-term guidance Capital Allocation • Progressive dividend reflecting the expectation of future cash flow generation and the long-term earnings potential of the Group • Share buybacks subject to market conditions
Page 31
M&A: Pipeline focus 31 Acquisition Pipeline Criteria European distributors across core specialities Independent retail pharmacies Market Access Commercialisation platforms Specialist distributors Retention of management talent and expertise Cultural fit: Innovative and ambitious Target ROCE 12%-15% within 3 years Divisional focus
Page 32
Ambition to deliver €200m EBITDA by 2028 32 Dividend 12% - 15% ROCE Progressive dividend Dividend 60% - 70% FCF Conversion At €200m EBITDA Net Bank Debt / EBITDA not to exceed 2.5x We expect over 80% EBITDA growth to be organic Group guidance | medium term metrics €99m €200m SC&R Medtech Pharma M&A >80% organic growth 2022 EBITDA 2028 EBITDA ambition
Page 33
33 Investment Case Experienced senior team, tried and tested Strong track record Compelling market opportunity in all 3 divisions Each division has an attractive competitive moat Clear pathway for success Greater capabilities = bigger opportunities
Page 34
Appendices 34
Page 35
Balance Sheet (€’000) 30 Jun 2026 31 Dec 2025 Goodwill and acquired intangible assets 520,732 519,474 IFRS 16 Right of Use Asset 145,738 145,536 Other non-current assets 274,810 238,328 Total non-current assets 941,279 903,338 Inventory 308,438 295,276 Trade & other receivables 326,955 349,713 Total current assets 635,393 644,989 Non-current IFRS 16 lease obligations 137,518 135,285 Other non-current liabilities 2,009 1,885 Total non-current liabilities 139,527 137,170 Trade & other payables 715,550 812,518 Current IFRS 16 lease obligations 19,444 22,334 Total current liabilities 734,994 834,852 Net assets 702,151 576,305 Financed by: Net bank debt 275,728 171,139 Equity 426,423 405,166 Total financed by 702,151 576,305 Summary Management Balance Sheet1 35 Appendices 1. Balance Sheet based on management classifications, not in accordance with IFRS financial statements
Page 36
Return on Capital Employed 36 Appendices 1. ROCE is calculated as the adjusted 12-month rolling operating profit expressed as a percentage of the adjusted average capital employed for the same period. The average capital employed is adjusted to ensure the capital employed of acquisitions & divestments completed during the period are appropriately time appo rtioned in the calculation of the average capital employed 12-Month Rolling 30 Jun (€’000) H1'24 H1’25 H1’26 Numerator Rolling 12 months operating profit 82,369 79,669 Adjustment for exceptional costs 4,806 14,087 Amortisation of acquisition related intangibles 3,432 3,547 Adjusted 12 months operating profit 90,607 97,303 Denominator Total equity 350,187 372,981 426,423 Net bank debt 143,609 197,535 275,728 Deferred contingent consideration 68,489 39,107 7,170 Deferred consideration payable - - 1,245 Total capital employed 562,285 609,623 710,566 Average capital employed 585,954 660,095 Adjustment for acquisitions & divestments1 - - Adjusted average capital employed 585,954 660,095 Return on capital employed 15.5% 14.7%
Page 37
Summary Group Financial Information 37 Appendices 1. Net of add back of depreciation charged in Cost of Sales Six months ended 30 June (€’000) H1’26 H1’25 Reported % Growth Revenue 1,591,855 1,485,492 7.2% Gross profit 236,490 219,651 7.7% Overheads & operating income1 (175,431) (162,156) 8.2% EBITDA 61,059 57,495 6.2% Depreciation & amortisation (18,380) (17,140) 7.2% Share-based payment expense (1,883) (1,883) 0.0% Exceptional items (5,396) (5,866) (8.0%) Operating profit 35,400 32,606 8.6% Net finance cost (including exceptional finance cost) (9,650) (9,768) (1.2%) Income tax (5,751) (5,345) 7.6% Profit after tax 19,999 17,493 14.3% Non-controlling interest (6) (20) (68.6%) Profit attributable to the owners 19,993 17,473 14.4% Basic EPS 7.7 6.6 16.7% Adjusted EPS 10.9 9.8 11.2%
Page 38
EBITDA Reconciliation 38 Appendices EBITDA is earnings before interest, tax, depreciation, amortisation, share-based payments and exceptional items Six months ended 30 June (€’000) H1’26 H1’25 Operating profit pre-exceptional 40,796 38,472 Share-based payments 1,883 1,883 Depreciation 14,520 13,777 Amortisation 3,860 3,363 EBITDA 61,059 57,495
Page 39
39 Contact Details Allan Smylie Head of Strategy and Investor Relations +353 (0)1 428 7777 investor.relations@uniphar.ie Q4 PR Public Relations Adviser to Uniphar Iarla Mongey +353 (0)1 475 1444